CD79A and Thrombocytopenia: We investigated the potential impact of circulating IgA-expressing putative B1 cells and soluble IgAs on the clinical severity of PUUV-HFRS by stratifying patients based on two independent factors reflecting disease severity: acute kidney injury (AKI) and thrombocytopenia.